v3.26.1
Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 06, 2026
Aug. 01, 2025
Jul. 30, 2025
Mar. 08, 2024
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 23, 2025
Sep. 15, 2025
Mar. 20, 2025
Nov. 16, 2024
AccountingPoliciesLineItems [Line Items]                                
Cash and cash equivalents         $ 4,800,000       $ 4,800,000              
Restricted cash         1,555,649       1,555,649   $ 1,231,168          
Shareholders deficit         2,387,244 $ 407,732 $ 529,701 $ (923,611) 2,387,244 $ 529,701 (1,232,410) $ (2,470,290)        
Net loss         2,123,884 1,954,683 1,793,774 2,027,579 4,078,567 3,821,353            
Net cash used in operating activities                 3,781,366 2,079,746            
Accumulated deficit         97,529,675       97,529,675   93,451,108          
Revenue from contract with customer excluding         961,138   $ 966,630   2,072,094 $ 1,360,202            
Allowance for credit losses         0       0   0          
Provision for income taxes                 0              
Unrecognized tax benefits         0       0              
Deferred tax assets         $ 17,900,000       $ 17,900,000   $ 19,000,000.0          
Deferred tax assets valuation allowance coverage percent         100.00%       100.00%   100.00%          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         5,447,697   6,064,253   5,447,697 6,064,253            
Unvested Restricted Stock Units [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         189,682   96,984   189,682 96,984            
Common Stock [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount             5,999,597   4,955,415 5,999,597            
Warrant [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount         302,600       302,600              
Two and Three Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding         $ 917,932   $ 794,615                  
Concentration risk percentage         95.50%   58.40%                  
Three and Four Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding                 $ 1,678,299 $ 1,101,653            
Concentration risk percentage                 81.00% 80.90%            
Seven And Four Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding                 $ 1,023,529              
Concentration risk percentage                 78.60%              
One And Two Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding                     $ 916,953          
Concentration risk percentage                     84.10%          
Five Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding         $ 709,245   $ 63,560                  
Concentration risk percentage         73.80%   6.60%                  
Four Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Non-US [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding                 $ 1,015,383 $ 111,893            
Concentration risk percentage                 49.00% 8.20%            
Five and Two Customers [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member] | Non-US [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Revenue from contract with customer excluding                 $ 1,214,940   $ 916,953          
Concentration risk percentage                 93.30%   84.10%          
Two CROs [Member] | Contract Research Organizations [Member] | Supplier Concentration Risk [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Concentration risk percentage         78.90%   91.10%   69.50% 85.90%            
Research services purchased         $ 517,282   $ 880,020   $ 1,168,985 $ 1,363,447            
One and Two CROs [Member] | Accounts Payable [Member] | Supplier Concentration Risk [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Concentration risk percentage                 51.90%   67.00%          
Accounts Payable         423,438       $ 423,438   $ 571,149          
Sales Agreement [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Stock Issued During Period, Value, New Issues $ 4,238,000                              
[custom:SaleOfStockPercentageOfGrossProceeds-0] 3.00%                              
Gates Foundation [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Proceeds from grants         3,092,136       3,092,136             $ 3,092,136
Revenue from contract with customer excluding         253,186       506,154              
Fondazione Biotecnopolo Di Siena Fbs [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Proceeds from grants                             $ 4,500,000  
Grants Receivable                             $ 2,432,756  
December Two Thousand Twenty Five Amendment [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Debt instrument convertible conversion price                         $ 1.05      
Mr Mark A Emalfarb [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Principal amount                           $ 1,000,000    
Common Stock [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Shareholders deficit         (48,693) (48,693) (42,390) (42,368) $ (48,693) $ (42,390) $ (48,442) (42,090)        
Net loss                        
Issuance of common stock upon settlement of convertible debt                       $ 910,000        
Conversion of convertible notes, shares                       556,623        
Shares issued   6,052,000                            
Public offering price, per share   $ 0.95 $ 0.95                          
Proceeds from issuance initial public offering     $ 4,900,000                          
Senior Secured Convertible Promissory Notes [Member]                                
AccountingPoliciesLineItems [Line Items]                                
Principal amount       $ 6,000,000                        
Interest rate       8.00%                        
Proceeds from Issuance of Senior Long-Term Debt       $ 5,824,326